Compass Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Compass Pathways (NASDAQ:CMPS) posted its quarterly earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08, Zacks reports.

Here are the key takeaways from Compass Pathways’ conference call:

• COMPASS expects to complete its rolling NDA submission for COMP360 within two weeks. The National Priority Voucher could support an FDA review target of roughly one to two months, although approval timing remains uncertain.
• The company reported strong commercial-launch preparation for a potential first-half 2027 TRD launch, including filled non-field commercial roles, expanding field-force recruitment, payer discussions, and engagement with more than 8,500 interventional psychiatry centers.
• Management highlighted COMP360’s reported rapid onset, durability potentially extending to 12 months, and infrequent dosing as key differentiators from existing treatment options. Market research found approximately 90% of surveyed interventional psychiatrists would prescribe it within the first year, though these findings reflect company-sponsored research.
• COMPASS said its PTSD registrational study is actively enrolling and identified additional potential expansion areas, including substance-use disorders, bipolar II disorder, and OCD. The company remains focused primarily on the TRD launch, with PTSD described as the next major indication opportunity.
• Launch execution still depends on DEA and state-level rescheduling, REMS implementation, reimbursement, and provider training. CPT Category III codes may take 12–18 months to transition to Category I, prompting planned patient-support and site-support programs to reduce early access and affordability barriers.

Compass Pathways Price Performance

CMPS stock traded down $0.43 during trading on Thursday, hitting $8.17. The company had a trading volume of 1,294,129 shares, compared to its average volume of 3,496,441. The business has a 50 day moving average of $12.57 and a 200 day moving average of $10.40. Compass Pathways has a fifty-two week low of $4.88 and a fifty-two week high of $15.87. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -2.33 and a beta of 2.43. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CMPS. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Thursday, October 15th. Jefferies Financial Group restated a “buy” rating on shares of Compass Pathways in a research note on Wednesday, September 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a report on Tuesday. Finally, Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target on the stock in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average target price of $23.14.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.